---
title: "Laquinimod - Relapsing Remitting Multiple Sclerosis"
sidebar: mydoc_sidebar
permalink: db06685-mesh-d020529-1.html
toc: false 
---


Path ID: `DB06685_MESH_D020529_1`
{% include image.html url="images/db06685-mesh-d020529-1.png" file="db06685-mesh-d020529-1.png" alt="db06685-mesh-d020529-1" %}

## Concepts

|------------|------|---------|
| Identifier | Name | Type    |
|------------|------|---------|
| MESH:C476223 | laquinimod | Drug |
| CHEBI:35472 | anti-inflammatory drug | ChemicalSubstance |
| CHEBI:63726 | neuroprotective agent | ChemicalSubstance |
| MESH:D020529 | Relapsing remitting multiple sclerosis | Disease |
|------------|------|---------|

## Relationships

|---------|-----------|---------|
| Subject | Predicate | Object  |
|---------|-----------|---------|
| Laquinimod | CHEMICALLY SIMILAR TO | Anti-Inflammatory Drug |
| Laquinimod | CHEMICALLY SIMILAR TO | Neuroprotective Agent |
| Anti-Inflammatory Drug | TREATS | Relapsing Remitting Multiple Sclerosis |
| Neuroprotective Agent | TREATS | Relapsing Remitting Multiple Sclerosis |
|---------|-----------|---------|

Comment: Mechanism of action of laquinimod on Relapsing remitting multiple sclerosis is not well understood. Available evidence suggests it as anti-inflammatory and neuroprotective agent based on in vivo experiments. The drug was withdrawn from phase III clinical trials

Reference: 
  - [https://go.drugbank.com/drugs/DB06685](https://go.drugbank.com/drugs/DB06685)
  - [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4798201/](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4798201/)
